The Jilin University-aligned OLED materials producer generated $168m in an IPO set to fund enhancements to its product range.

The Alibaba, Xiaomi, Foxconn, UCar and Duowan-backed smart electric carmaker has floated in the US through an offering valuing it in excess of $21bn.

Desktop Metal, backed by a large consortium of corporates, will merge with special purpose acquisition company Trine to list on the NYSE at a $2.5bn valuation.

Gastrointestinal and liver disease-focused Metacrine has filed to go public having raised $125m from investors including Eli Lilly.

Volvo Cars, Corning and Cornes-backed lidar technology developer Luminar is merging with a special purpose acquisition vehicle to form a company with an expected $3.4bn valuation.

The SK Telecom, iA Financial, Foxconn and Fujifilm-backed X-ray technology developer priced the offering at the top of its range.

The protein degradation drug developer's valuation has rocketed following an offering that achieved exits for Vertex Pharmaceuticals, Pfizer, Sanofi, Amgen and Merck & Co.

Eli Lilly and WuXi Biologics-backed biologics developer Inhibrx floated at the midpoint of its range having previously raised $135m in debt and equity financing.

The immuno-oncology company – co-founded by Juno Therapeutics, a spinout of several institutions – is reportedly seeking $250m to $300m in a Hong Kong offering.

Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.